Serum Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for Early Renal Dysfunction in Adult Egyptian Patients with \(\beta\)-Thalassemia Major


The Department of Internal Medicine, Faculty of Medicine, Tanta University

Abstract

Background: Renal dysfunction in thalassemia may occur before the occurrence of any symptoms. Induction of NGAL after kidney injury precedes the elevation of classical markers for kidney damage, which made it a promising marker for renal dysfunction in \(\beta\)-thalassemia, major.

Aim of the Work: To assess value of serum NGAL in patients with \(\beta\)-thalassemia major as an early marker of renal impairment.

Patients and Methods: The present study enrolled 70 subjects and they were classified into two main groups:

- Group (I): 20 apparently healthy normal volunteers.
- Group (II): 50 multi-transfused \(\beta\)-thalassemia major patients.

Which subdivided according to chelation therapy into two subgroups:

- Subgroup (I): On regular iron chelation therapy.
- Subgroup (II): Without chelation therapy.

Results: In our study serum NGAL was significantly elevated in group II compared to control group. Also in our study, we found a direct correlation between NGAL and urea, creatinine, eGFR, ferritin, transferrin saturation while there was inverse correlation between NGAL and hemoglobin, \(\beta\)2-microglobulin.

Conclusion: NGAL could be considered as early predictor of renal dysfunction in thalassemia.

Key Words: Thalassemia major – Renal dysfunction – NGAL.

Introduction

NEUTROPHIL Gelatinase-Associated Lipocalin [NGAL] is a very early and sensitive biomarker of kidney injury. The origin and time course of NGAL were assessed in several experimental and clinically relevant renal diseases. Neutrophil Gelatinase-Associated Lipocalin [NGAL] is a differ-
a blood sample. However, this correlates poorly with the gold standard measurement of kidney function because 50% of people, despite a normal measured serum creatinine on a routine blood test, have evidence of impaired kidney function [6]. So there is an urgent need for early predictive biomarkers of renal impairment in Beta-thalassemia major as early intervention can significantly improve the prognosis [7].

Patients and Methods

This is a cross-sectional study carried out at Tanta University Hospital and Tanta Health Insurance Hospital starting from July 2016 to January 2017.

The study included two groups:

First group [control group]: It included 20 apparently healthy volunteers as a control group (10 males and 10 females) with mean age 33.26 ± 5.43 years.

Second group [patients group]: It included 50 multi-transfused β-thalassemia major patients (27 males and 23 females). Their mean age was 30 ± 7.2 years.

Where they subdivided according to chelation therapy into to subgroups:

Subgroup (I): On regular iron chelation therapy. This group included 31 patients (17 males and 14 females). Their mean age was 29.03 ± 5.95 years.

Subgroup (II): without chelation therapy. This group included 19 patients (10 males and 9 females). Their mean age was 30.36 ± 9 years.

The inclusion criteria:
1- Patient age >18 of both sexes.
2- Patients with β-thalassemia major as evidenced by the following criteria at the time of initial diagnosis (age at presentation was less than 2 years with a mean hemoglobin level of 6-7g/dl, HbF >50%, and HbA2 <4%).

The exclusion criteria:
1- Patients with other hemoglobinopathies.
2- Patients with other hemolytic anemia.
3- Patients with systemic illness (heart failure, hepatic diseases, or diabetes mellitus).
4- Patients with clinical or laboratory evidence of other causes of renal diseases.

Ethical considerations:

Informed written consent obtained from all patients included full explanation of the benefits and risks of the study.

Methods:

All patients in the study were subjected to:
1- Full history taking.
2- Complete clinical examination.
3- Imaging including: Abdominal ultrasound.
4- Laboratory tests including:
   A- Routine investigations:
   - Complete blood picture.
   - Serum Ferritin (ng/dl).
   - Transferrin saturation (%).
   - Random blood sugar (mg/dl).
   - C reactive protein (mg/dl).
   - Urine analysis.
   - Blood urea (mg/dl) and serum creatinine (mg/dl).
   - Estimated glomerular filtration rate by Cockcroft-Gault Equation (ml/min/1.73m²).
   B- Special laboratory tests:
   - Serum Beta-2 microglobulin (mg/l).
   - ELISA technique for estimation NGAL in serum.

Statistical analysis:

Statistical presentation and analysis of the present study was conducted using the mean, standard deviation and chi-square test by SPSS V.20.

Results

I- Demographic data:

Study population were compared according to age (Table 1) with no statistically significant difference as p-value was 0.086 (>0.05).

The two subgroups were compared according to age (Table 2) with no statistically significant difference as p-value was 0.531 (>0.05).

NGAL (ng/ml) mean values were 22.27 with SD 7.1 in group (II) and 9.14 with SD 3.02 in-group (I). There was a highly significance difference as (p<0.0001) as presented in (Table 3).

NGAL (ng/ml) mean values were 18.90 with SD 5.27 in subgroup (I) and 27.75 with SD 6.30 in subgroup (II) in patient group. There was a highly significance difference as (p<0.0001) as presented in (Table 4).
Table (1): Age means values of the two groups.

<table>
<thead>
<tr>
<th></th>
<th>Patient group (n=50)</th>
<th>Control group (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rang</td>
<td>21-54</td>
<td>20-45</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>29.54±7.21</td>
<td>32.7±5.87</td>
</tr>
<tr>
<td>t-value</td>
<td>1.74</td>
<td>0.086</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table (2): Age means values of patient sub groups.

<table>
<thead>
<tr>
<th></th>
<th>Sub group (1) (n=31)</th>
<th>Sub group (2) (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rang</td>
<td>21-42</td>
<td>21-54</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>29.03±5.95</td>
<td>30.36±9</td>
</tr>
<tr>
<td>t-value</td>
<td>0.630</td>
<td>0.531</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table (3): NGAL mean values of the two groups.

<table>
<thead>
<tr>
<th></th>
<th>Patient group (n=50)</th>
<th>Control group (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rang</td>
<td>9.40-39</td>
<td>3.4-14</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>22.27±7.1</td>
<td>9.14±3.02</td>
</tr>
<tr>
<td>t-value</td>
<td>7.959</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table (4): NGAL mean values of the two sub groups.

<table>
<thead>
<tr>
<th></th>
<th>Sub group (1) (n=31)</th>
<th>Sub group (2) (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rang</td>
<td>9.4-29.1</td>
<td>12.6-39</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>18.90±5.27</td>
<td>27.75±6.30</td>
</tr>
<tr>
<td>t-value</td>
<td>5.30</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Discussion

The survival of the patients with β-thalassemia major has improved recently due to both effective oral chelating agents and novel imaging modalities pointing visceral iron overload earlier. Extending patients survival leads to many organ dysfunctions [8]. Regarding renal injury, several factors might play role in patients with thalassemia. Chronic hypoxia, ongoing hemolysis, iron overload owing to transfusions and possible nephrotoxicity of chelators are well-known reasons of the deterioration in renal functions [9].

The principal finding of the present study was that that there was a high significant difference between the two groups, also there was a significant difference between the two sub groups regarding the serum neutrophil gelatinase-associated lipocalin levels.

Ioannis P et al., (2009); [10] reported in a Greek study included 150 patients that NGAL levels were significantly increased in the thalassemia patients studied compared to normal controls.

Similar findings were reported by Mehryar H et al., (2008); [11] who reported that adult beta-thalassemia patients upregulated NGAL expression compared with the normal sample and explained it by upregulation that play an important role in decreasing iron in thalassemia patients.

Gulcihan O et al., (2014); [12] in agreement with us also reported that the NGAL is higher in patients group compared to control group.

According to Aikaterini P et al., (2014); [13] many reasons are contemplated for elevated NGAL at thalassemia patients including anemia/hypoxia, renal damage, and iron homeostatic disturbances.

Alok H (2017); [14] submitted a research paper at SPADS conference discussing NGAL as indicator of renal injury in Indian beta Thalassemia disease children. He found a positive significant correlation between duration of chelation and serum NGAL.

Conclusion:

- Renal dysfunction in thalassemia may occur before the occurrence of any symptoms or complications and may be explained by anemia/hypoxia, repeated blood transfusion, iron overload and by toxicity of chelators.
- NGAL could be considered as early predictor of renal tubular and glomerular dysfunction in thalassemia.

References

دراسة مستوى نيتروفيل جيلاتيناز المرتبط بالليبيوكاليكن كدالة مبكرة للقصور الكلوي في مرضى آنيميا البحر المتوسط بيتا

الأنيميا البحر الأبيض المتوسط هو حالة تؤثر على كرات الدم الحمراء، وتنتشر في منطقة حوض البحر الأبيض المتوسط. ينتج هذا المرض عن خلل الجينات وسبب الآنيميا المزمن وهو حمض قد يؤثر على الأسنان، وهو فين يتأثر في جين الدم. يتراوح بسبب الرئة الكبيرة، وهو مرتبط بالمرض. دراسة الكاسيا، تتضمن الأنيميا البحر الأبيض المتوسط إلى أنواع مختلفة والأكثر شيوعًا منها في النوع بيتا الذي تتميز بجودة قصور في تكيس للسلالج الجليدي بيتا ومع تطور طرق علاج هذا النوع من الآنيميا عن طريق تقليل الدم المتكرر واستخدام أنواع جديدة من المواد التي تقلل من نسبة الحديد في الدم وأعضاء الجسم يظهروا مضاعفات جديدة في مرضى الأنيميا البحر الأبيض المتوسط ونتيجة الحالة إلى دلالات مبكرة للقصور الكلوي لعلاجنا بمجرد أن يتولى إلى فشل كلوي وقليل فرص علاجه.

أما البحث على سبعين شخصا من البالغين وهم متضمنين كالتالي:

- المجموعة الأولى: عشرون شاباً أصحاء كمجموعة ضابطة.
- المجموعة الثانية: خمسون مريض آنيميا البحر المتوسط من النوع بيتا. تم تقسيم هذه المجموعة إلى واحد وثلاثين مريض يتولون علاج مساعد لخفض نسبة الحديد بالدم (عامل خالي) وتسعة عشر مريض لا يتولون علاج مساعد لخفض نسبة الحديد بالدم. تم أخذ المواقفة المسبقة من جميع المشاركين.

أجرت الدراسة على الساكن أكثر من 18 عام من الجنسين في مرضى آنيميا البحر المتوسط من النوع بيتا وتم تشخيصها بالمرض، الفحص الإكلينيكي والمعمل.

وقد أظهرت النتائج أنه:

- قد يحدث خلل نيتروفيل في الأنيميا البحر الأبيض المتوسط. قد يظهر مصاب بإصابة أو مضاعفات ويمكن تقديره بفحص الدم ونقل الدم المتكرر والترسيب الزائد للحديد.
- ومساهمة المواد الخالية للحديد.

عندما تحلل النتائج بين المجموعتين، لم تظهر فرقًا دلاليًا إحصائيًا بين المجموعتين فيما يتعلق بمستوى نيتروفيل جيلاتيناز المرتبط بالليبيوكاليكن وبالتالي يمكن اعتبار إرتفاع نسبة نيتروفيل كمؤشر مبكر للقصور الكلوي.